阿昔洛韦(Acyclovir) - 药物靶点：DNA-directed DNA polymerase_在研适应症：疱疹性角膜炎，唇疱疹，单纯疱疹病毒性脑炎_专利_临床

概要

基本信息

简介Acyclovir是一种合成嘌呤类似物，商品名为ZOVIRAX，其对疱疹病毒类型1（HSV-1）、2（HSV-2）和水痘-带状疱疹病毒（VZV）具有体外和体内的抑制活性。Acyclovir的抑制活性是高度选择性的，因为它与HSV和VZV编码的胸腺嘧啶激酶（TK）酶具有亲和力。这种病毒酶将acyclovir转化为一种核苷酸类似物——acyclovir单磷酸。单磷酸经过细胞鸟苷酸激酶的进一步转化，形成二磷酸和三磷酸。体外，acyclovir三磷酸可停止疱疹病毒DNA的复制。ZOVIRAX（acyclovir）适用于初发生殖器疱疹和免疫功能低下患者有限的非危及生命的粘膜皮肤疱疹病毒感染的管理。Aciclovir于1974年由Burroughs Wellcome（现为GlaxoSmithKline的一部分）获得专利，并于1981年获得英国批准。

药物类型

小分子化药

别名

Aciclovir、Aciclovir (JP17/INN)、Acycloguanosine

+ [37]

靶点

DNA-directed DNA polymerase

作用机制

DNA-指导DNA聚合酶抑制剂

治疗领域

感染神经系统疾病眼部疾病+ [4]

在研适应症

疱疹性角膜炎唇疱疹单纯疱疹病毒性脑炎+ [4]

非在研适应症

水痘HIV感染

原研机构

Burroughs Wellcome

在研机构

湖北科益药业股份有限公司

Pfizer Australia Pty Ltd.Bausch Health US LLC

+ [4]

非在研机构

Glaxo Wellcome SAMylan Pharmaceuticals, Inc.

GSK Plc

+ [1]

最高研发阶段批准上市

首次获批日期

英国 (1981-01-01),

单纯疱疹

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C8H11N5O3

InChIKeyMKUXAQIIEYXACX-UHFFFAOYSA-N

CAS号59277-89-3

关联

134

项与阿昔洛韦相关的临床试验

NCT05452928 / Not yet recruiting临床4期IIT

Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)

To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation

开始日期2025-06-01

申办/合作机构

Aalborg University Hospital

CTR20242987 / CompletedN/A

阿昔洛韦片在健康受试者中随机、开放、两制剂、单次给药、两周期、两序列空腹和餐后状态下的生物等效性试验

主要目的：以广东彼迪药业有限公司提供的阿昔洛韦片为受试制剂，按生物等效性试验的有关规定，与Glaxo Smithkline K.K.持有グラクソ·スミスクライソ株式会社生产的阿昔洛韦片（商品名：Zovirax®，参比制剂）对比在健康人体内的吸收速度及吸收程度，考察两制剂的人体生物等效性。次要目的：观察受试制剂阿昔洛韦片和参比制剂阿昔洛韦片（Zovirax®）在健康受试者中的安全性。

开始日期2024-08-26

申办/合作机构

广东彼迪药业有限公司

NCT06558838 / Enrolling by invitation临床2期IIT

A Randomized, Parallel Group, Pilot Study to Assess Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Active Comparator (Abreva) in the Suppression of Herpes Simplex Virus Eruptions in Subjects with a History of Herpes Labialis

This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 40 subjects with documented herpes labialis. Patients will be treated with the study drug, acyclovir-penciclovir cream, or the active comparator of Abreva.
Potential subjects will be assessed during a screening visit that must take place no greater than 2 weeks prior to the Day 1 (Baseline) visit. During the screening period, subjects that meet all other entry criteria will undergo Ultraviolet susceptibility testing to determine the subject's individual minimal erythema dose (MED). Ultraviolet susceptibility testing takes place over two days with exposure to Ultraviolet light on specified regions on the subject's back followed by an assessment of the exposed areas 24 hours later to identify the MED. Subjects who have a measurable MED will be allowed to enroll in the study. Each subject will be randomly assigned in a 1:1 ratio to receive either acyclovir-penciclovir cream or Comparator (Abreva).
Patients who express a cold sore will track the lesion with a diary card to rate their pain levels, and any unusual symptoms at Day 1, Day 3, Day 5, Day 7, and Day 10. Patients may also take photographs of the lesion throughout the study.

开始日期2024-08-19

申办/合作机构

University of Utah

100 项与阿昔洛韦相关的临床结果

登录后查看更多信息

100 项与阿昔洛韦相关的转化医学

登录后查看更多信息

100 项与阿昔洛韦相关的专利（医药）

登录后查看更多信息

9,804

项与阿昔洛韦相关的文献（医药）

2025-02-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Nitrogen dioxide sterilization of a set of five ophthalmic active pharmaceutical ingredients: Impact on impurity profile and content

Article

作者: Meyers, Anke ; Schepdael, Ann Van ; Van Schepdael, Ann ; Vanneste, Elias ; Haghedooren, Erik ; Speleers, Quinten ; Krupianskaya, Karyna ; DeMent, Aaron ; Gillet, Annick ; Croonenborghs, Bart

Literature about sterilization of pharmaceutical substances is limited. The aim of this study was to evaluate the effect of nitrogen dioxide (NO₂) sterilization, a new emerging technology, on five different ophthalmic active pharmaceutical ingredients, i.e., tetracycline hydrochloride, aciclovir, dexamethasone, methylprednisolone, and triamcinolone. The NO₂ process concentrations tested were 5, 10, and 20 mg/L. The applied temperature was 21 °C and the relative humidity 30 %. The process cycle consisted of two pulses with a dwell time of 10 min each. Non-processed samples were used as a blank. The effect of the sterilization method was assessed by high performance liquid chromatography coupled to an ultraviolet/visible detector, used for the quantitative analysis of the degradation products and the relative content of the evaluated ophthalmic medicines. For tetracycline hydrochloride and aciclovir, an increase of impurities was observed by increasing the NO₂ concentration. The maximum permissible NO₂ concentrations were estimated to be 10 mg/L and 2.5 mg/L, respectively, considering the requirement for the impurities to be within the limit stated in the European Pharmacopoeia (Ph. Eur.). For both compounds, samples subjected to 20 mg/L NO₂ demonstrated a significant difference in content compared to the non-processed sample. For methylprednisolone, dexamethasone, and triamcinolone, impurities complied with the limits of the Ph. Eur. for each NO₂ concentration and relative contents were not significantly affected. Sterilization of tetracycline hydrochloride and aciclovir with NO₂ is not recommended due to extensive degradation. NO₂ sterilization of methylprednisolone, dexamethasone, and triamcinolone could find its application within the aseptic processing procedure of related pharmaceuticals.

2025-01-01·CORNEA

Efficacy and Safety of Amenamevir, a Helicase-Primase Inhibitor for the Treatment of Acyclovir-Resistant Herpes Simplex Virus 1 Keratitis

Article

作者: Barreau, Emmanuel ; Haigh, Oscar ; Fernandez, José ; Rousseau, Antoine ; Vauloup-Fellous, Christelle ; Boucher, Rafael ; Labetoulle, Marc ; Boutolleau, David ; Burrel, Sonia

Purpose::

The purpose of this study was to describe the efficacy and tolerance of amenamevir (AMNV), an inhibitor of the viral helicase-primase, for the treatment of recalcitrant herpes simplex keratitis (HSK) caused by acyclovir-resistant (ACVR) herpes simplex virus 1 strains.

Methods::

In this retrospective case series, 6 consecutive patients with HSK caused by an ACVR herpes simplex virus 1 strain with a failure of conventional antiviral therapy were included after having been treated with AMNV (there was no control group of comparable patients for whom previous treatment would have been continued despite its inefficacy). Medical files were assessed for clinical data including reason(s) for AMNV introduction (frequent recurrences despite appropriate preventive antiviral treatment and/or clinical resistance to suppressive antiviral treatment of an ongoing clinical relapse), genotypical resistance to herpes simplex virus 1 documentation, immune status, clinical types and number of HSK episodes before and during AMNV treatment, adverse effects observed during AMNV treatment, and best corrected visual acuity.

Results::

Of 6 patients, 4 (66%) did not experience a single recurrence during AMNV therapy while 2 others had recurrences (1 over 24 months of treatment and 2 over 23 months, ie two-fold less frequently than with conventional preventive treatment). On the overall history of these 6 patients, AMNV appeared to be associated with a reduction in HSK recurrences, with a mean of only 0.02 ± 0.04 episodes/month during follow-up under AMNV as compared to 0.14 ± 0.04 episodes/month in the year preceding AMNV introduction (P = 0.03). Improvement in vision acuity was also observed (mean best corrected visual acuity 0.17 ± 0.12 logarithm of the minimum angle of resolution at the end of follow-up vs. 0.30 ± 0.35 before AMNV onset), albeit nonsignificant probably due to the limited number of patients (P = 0.38). Neither clinical nor biological adverse effects were observed while under AMNV during the follow-up (16.5 ± 5.8 months).

Conclusions::

Although there was no control group, AMNV may be a valuable option to reduce ACVR HSK recurrences.

2025-01-01·NEUROTOXICOLOGY

Acyclovir provides protection against 6-OHDA-induced neurotoxicity in SH-SY5Y cells through the kynurenine pathway

Article

作者: Ozkaraca, Mustafa ; Gulluce, Medine ; Okkay, Ufuk ; Sezen, Selma ; Burul, Feyza ; Yesilyurt, Fatma ; Gulsahin, Yusuf ; Karadayi, Mehmet

Parkinson's disease is one of the most prevalent neurodegenerative disorders worldwide. The kynurenine pathway associated with oxidative stress and neuroinflammation is recognized to contribute to its pathophysiology, although the exact mechanism is not fully elucidated. In neuroinflammation, IDO-1 catalyzes the conversion of tryptophan to neurotoxic QUIN through the kynurenine pathway. Consequently, QUIN increases oxidative stress via nNOS and NMDA, which causes neurodegeneration. Few studies have reported on the effect of different antiviral drugs in Parkinson's disease; the exact mechanism is still unknown. The antiviral acyclovir has been shown to have neuroprotective properties and can cross the blood-brain barrier. We examined acyclovir's effects and potential mechanisms in the 6-OHDA-induced in vitro model of Parkinson's disease in SH-SY5Y cells using biochemical, immunocytochemical, and in silico methods. MTT assay demonstrated that acyclovir significantly decreased cell mortality induced by the neurotoxic 6-OHDA at dosages of 3.2 µM, 6.4 µM, 12.8 µM, 25.6 µM, and 51.2 µM. In immunocytochemical analysis, acyclovir treatment decreased α-synuclein and TNF-α expressions in cells. In biochemical analyses, while IL-17A and TOS levels decreased depending on varying doses (1.6 µM, 3.2 µM, 6.4 µM, 12.8 µM), TAC levels increased. Using in silico analyses to investigate the mechanism showed that acyclovir docked with TNF-α, IL-17A, IDO-1, nNOS, α-synuclein, and NMDA. The findings demonstrated that acyclovir had neuroprotective effects by modulating the kynurenine pathway and decreasing neurodegeneration via QUIN inhibition in an in vitro Parkinson's disease model. Although the mechanisms of acyclovir's effects in Parkinson's disease are unclear, the results obtained from the experiments are encouraging.

155

项与阿昔洛韦相关的新闻（医药）

2024-12-13

·佰傲谷BioValley

3期临床成功，股价大涨，然而……

近来，好久没有关于溶瘤病毒的消息了。近日，Candel Therapeutics倒是披露了其病毒免疫疗法CAN-2409在中高危局部前列腺癌的3期成功。该消息的披露，使得该公司的股价在早盘上涨超过200%。但是随着通稿的解读，CAN-2409暗藏的两个雷点：（1）同是局部前列腺癌，中高危的3期成功，低中危的2期失败了；（2）成功的3期，说是按照与FDA达成的特别方案评估（SPA）进行的，但是Candel公司对临床方案进行了未经批准的调整，以及此前从未使用过的临床终点是否能够获得监管认可。并不明朗的前景，使得Candel公司的股价在当日收盘时回落至7.75美元/股，涨幅为68.11%。病毒免疫疗法CAN-2409 CAN-2409是一种研究性的、现成的、复制缺陷型腺病毒，旨在将单纯疱疹病毒胸苷激酶（HSV-tk）基因特异性递送至患者的肿瘤细胞。HSV-tk可以在局部将口服的valacyclovir转化为有毒的代谢物acyclovir，以杀死附近的肿瘤细胞。该候选疗法通过直接注射到肿瘤组织内，可杀死局部的肿瘤细胞，导致微环境中肿瘤特异性新抗原的释放，进而激活全身的抗肿瘤应答。此外，局部注射将免疫应答局部聚焦于肿瘤，能够最大限度地减少与全身静脉给药相关的全身毒性。目前，CAN-2409正在非小细胞肺癌（NSCLC）、临界可切除胰腺导管腺癌（PDAC）和局部非转移性前列腺癌中评估疗效。迄今为止，已经有超过1000多名患者接受了CAN-2409给药。 CAN-2409联合前药（valacyclovir）已被美国FDA授予快速通道资格，用于治疗对一线PD-(L)1抑制剂治疗耐药且没有激活分子驱动突变或在定向分子治疗中取得进展的PDAC、III/IV期NSCLC、局部原发性前列腺癌。FDA还授予了CAN-2409孤儿药资格认定，用于治疗PDAC。成功的3期研究在这项随机2：1、双盲、安慰剂对照、多中心临床试验中，共招募了745名患者（意向治疗人群，ITT），以评估CAN-2409加前药（伐昔洛韦）病毒免疫疗法联合标准护理外照射放疗治疗中高危局部前列腺癌患者的无病生存期的改善效果及安全性。患者被随机分配和分层接受短期（< 6个月）雄激素剥夺治疗（ADT）。招募人群的中位随访时间为50.3个月。主要结局指标包括在放疗结束后2年进行活检，以评估是否存在肿瘤复发。局部或全身复发和全因死亡也是DFS终点的一部分。研究结果显示，该研究达到了其主要终点，与对照组相比，CAN-2409治疗组的无病生存率有统计学意义改善。主要结果包括：在ITT中，CAN-2409联合放疗组（n=496）相比单纯放疗组（n=249）的无病生存期（DFS）具有统计学意义的改善（p=0.0155; HR 0.7）。与安慰剂对照组相比，CAN-2409治疗组在54个月时观察到的DFS相对改善14.5%。在接受短期ADT和未接受ADT的患者中，均观察到DFS改善。在一项针对前列腺特异性结果（如其他原因导致的删失死亡率）的分析中，CAN-2409显示出显著的效果(p=0.0046；hr 0.6)对前列腺无癌生存率的影响。与安慰剂对照组相比，CAN-2409治疗组达到前列腺特异性抗原（PSA）最低点（<0.2 ng/ml）的患者比例增加（67.1% vs. 58.6%；p<0.0164）。 2年后活检观察到，CAN-2409治疗组中的病理完全缓解（pCR）为80.4%，对照组为63.6%（p=0.0015）。 CAN-2409的安全性与先前研究一致，未发现新的安全信号。最常见的CAN-2409相关不良事件包括流感样症状、发热和寒战，通常为轻度至中度，具有自限性。低中危的2期失败值得注意的是，Candel公司同日披露，CAN-2409在低至中度风险的局部前列腺癌的一项2期研究中未达目标。该项2期研究旨在评估CAN-2409免疫疗法在接受主动监测的低至中度风险局部前列腺癌患者的有效性。参与者将以2：1的比例随机分配到CAN-2409组或安慰剂对照组。该研究的主要终点是无进展生存期（PFS），次要终点是1年里程碑的阴性活检率和发生不良事件的患者百分比。最新披露的数据显示，在190名接受主动监测的低至中度风险局部前列腺癌患者中，在接受根治性治疗的时间和治疗1年后进行活检获得阴性（无前列腺癌）的患者比例在数值上有所改善，但是并没有达到统计学意义。安全性方面，与3期临床试验报告基本一致。计划寻求监管批准除了在中高危和低中危的前列腺癌研究数据上的两级反转之外，在监管上，Candel公司也进行了一波极限拉扯。事实上，基于CAN-2409在中高危前列腺癌的3期试验积极结果，Candel打算与FDA就CAN-2409在中高危局部前列腺癌中的监管途径展开讨论。在一则声明中，Candel总裁兼首席执行官Paul Peter Tak表示：“这项研究（CAN-2409与放疗联用治疗中高危局部前列腺癌患者的3期临床试验）是根据与美国FDA就研究设计的关键方面达成的特别方案评估（SPA）进行的，意味着该研究产生的安全性和有效性数据可能足以使公司寻求CAN-2409用于该适应症的监管。” FDA的SPA流程是一种针对临床试验设计和实施的详细评估方法。这一过程的目的是确保临床试验的设计能够满足FDA的科学和监管要求，从而充分支持药物的监管申请。但是SPA并不能保证监管审查的任何特定结果，也可能不会导致成功的审查和批准程序。但是，令人在意的一点在于，Candel公司于上个月表示，虽然已经为CAN-2409的3期临床获得了SPA协议，但是随后对方案进行了细微的修改，并且没有获得与修改后方案相关的SPA修正。另外，CAN-2409所使用的主要终点在以前的试验中并没有使用过，尽管这一终点已经与FDA达成了SPA协议，但是还是可能存在不被监管机构所认可的风险。 Candel公司计划在2026年第四季度获得CAN-2409的批准，在Candel发布的2024年第三季度财报中，其现有的现金和现金等价物将足以为支持到2025年第一季度末的当前运营计划提供资金。小结在临床研究和监管之外，小编查询到在2024年11月，Candel公司的董事和股东进行了多笔内部交易，包括Tak Paul Peter在内的多名高管、董事和股东都进行了卖出。另外，由于低中危局部前列腺癌研究的失败，抵消了一部分CAN-2409在中高危局部前列腺癌的3期成功。当日Candel公司股价最高涨幅来到200%以上，但是截至收盘，涨幅为68.11%。中高危的成功和低中危的失败在拉扯，SPA协议和未经修正的临床调整，都使得CAN-2409的监管前景不太明朗。参考资料： 1.https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-can-2409-achieved-primary-endpoint 2.https://www.fiercebiotech.com/biotech/candel-burns-bright-phase-3-prostate-cancer-win-sends-stock-200 本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

免疫疗法临床3期孤儿药快速通道临床2期

2024-12-11

·药明康德

80%前列腺癌患者达到病理学完全缓解，创新免疫疗法达到3期临床主要终点

▎药明康德内容团队编辑 Candel Therapeutics公司今日宣布，在研病毒免疫疗法CAN-2409与放疗联用，在治疗局部前列腺癌患者的3期临床试验中达到主要终点。在中高危患者中显著改善患者的无病生存期（DFS）。这项随机双盲、安慰剂对照、多中心临床试验纳入了745名患者，旨在评估CAN-2409联合valacyclovir和标准外照射放疗对中高危局部前列腺癌患者无病生存期的改善效果及安全性。 CAN-2409是一种复制缺陷的腺病毒，可将编码单纯疱疹病毒胸苷激酶（HSV-tk）的基因递送入癌细胞。HSV-tk可以将口服的valacyclovir转化为有毒的代谢物acyclovir。该候选疗法通过直接注射到肿瘤组织内，可杀死局部的肿瘤细胞，导致微环境中肿瘤特异性新抗原的释放，进而激活全身的抗肿瘤应答。此外，局部注射将免疫应答局部聚焦于肿瘤，能够最大限度地减少与全身静脉给药相关的全身毒性。试验结果显示：在意向治疗人群中，CAN-2409联合放疗组（n=496）相比单纯放疗组（n=249），无病生存期显著改善（HR=0.7，p=0.0155）。 CAN-2409治疗组患者达到前列腺特异性抗原（PSA）最低点（<0.2 ng/ml）的比例显著增加（67.1%比58.6%；p<0.0164）。 CAN-2409治疗组患者中，在治疗两年后80.4%达到病理学完全缓解（pCR），对照组为63.6%（p=0.0015）。 CAN-2409的安全性与先前研究一致，未发现新的安全信号。最常见的不良事件包括流感样症状、发热和寒战，通常为轻度至中度。仅在美国，每年就有超过10万名男性确诊为局部前列腺癌，其中超过5万人接受放射治疗。前列腺癌仍是美国男性癌症死亡的第二大原因，而在过去20多年里，局部非转移性前列腺癌的标准治疗并未发生重大变化或引入新疗法。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival. Retrieved December 11, 2024, from https://www.globenewswire.com/news-release/2024/12/11/2995251/0/en/Candel-Therapeutics-Announces-CAN-2409-Achieved-Primary-Endpoint-in-Phase-3-Prostate-Cancer-Trial-Showing-Significantly-Improved-Disease-Free-Survival.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

免疫疗法放射疗法临床3期临床结果

2024-12-11

·Pharmaceutical Technology

Better prevention and treatment options needed for genital herpes, WHO says

There is currently no cure for genital herpes, though medication can control the infection. Image credit: Shutterstock / Richard Juilliart. A World Health Organization (WHO) director has called for “better prevention and treatment options” after the agency released new estimates of genital herpes prevalence. Dr Meg Doherty, director of global HIV, hepatitis and sexually transmitted infections programmes, has said that more needs to be done, not only to reduce the transmission of genital herpes but said this will also reduce the transmission of HIV. “While most people with a genital herpes infection experience few symptoms, with so many infections genital herpes still causes pain and distress for millions globally and strains already overburdened health systems,” said Dr Doherty. Updated figures show that around 846 million aged between 15 and 49 years are living with the infection. This total translates to more than one in five in this age group globally living with the disease, as per a WHO 11 December press release. Genital herpes is caused by two types of herpes simplex virus (HSV) – HSV-1 and HSV-2. WHO stated that HSV-2 is more serious from a public health perspective since it is more likely to cause recurrent outbreaks, along with a higher chance of contracting human immunodeficiency virus (HIV). Currently, there is no cure for genital herpes – although there are approved antivirals that relieve symptoms. In the US, this includes Novartis ’ Famvir (famciclovir), GSK ’s Valtrex (valacyclovir), and acyclovir. Although the antivirals do not remove the virus from the body, they slow the growth of herpes, making it easier for the immune system to control the infection and reduce the frequency of outbreaks. Valtrex and Famvir were approved by the US Food and Drug Administration (FDA) for genital herpes in 2003 and 2006 respectively. Since then, there has been little change in available treatments. “Not enough has been done to address this common infection,” said Dr Sami Gottlieb, a medical officer within WHO’s Department of Sexual and Reproductive Health and Research, who also served as author of the report detailing the updated infection figures. “Expanded research and investment in developing new herpes vaccines and therapies, and their equitable use, could play a critical role in improving quality of life for people around the world,” Dr Gottlieb added. An HSV vaccine could come courtesy of Moderna or BioNTech , who have candidates in clinical trials. Moderna’s therapeutic candidate, an mRNA vaccine called mRNA-1608 is currently in Phase II development while BioNTech’s prophylactic candidate, also mRNA-based BNT-163, is in Phase I development. Developing a vaccine that is effective against HSV has proved difficult, however. A setback occurred in September this year when GSK announced it was discontinuing its vaccine candidate following a Phase I/II failure. Although deemed safe, the vaccine lacked efficacy in reducing lesions in patients with recurrent genital herpes.

疫苗上市批准临床2期临床1期

100 项与阿昔洛韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00222	阿昔洛韦	D06BB03 J05AB01 S01AD03	DB00787

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疱疹性角膜炎	日本	Nitto Medic Co., Ltd.	2007-01-23
唇疱疹	美国	Bausch Health US LLC	2002-12-30
单纯疱疹病毒性脑炎	澳大利亚	Pfizer Australia Pty Ltd.	1996-08-19
水痘	美国	Mylan Pharmaceuticals, Inc.	1985-01-25
带状疱疹	中国	湖北科益药业股份有限公司	1985-01-01
水痘带状疱疹病毒感染	中国	湖北科益药业股份有限公司	1985-01-01
生殖器疱疹	美国	Bausch Health US LLC	1982-03-29
单纯疱疹	英国	Burroughs Wellcome	1981-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床3期	美国	Glaxo Wellcome SA	2001-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


#4815 (ERA2023)	N/A	带状疱疹	-	Acyclovir/Valacyclovir	糧簾鑰襯願築窪餘積淵(衊觸艱糧夢憲艱獵鑰衊) = 廠鹹憲衊鏇鬱積齋築廠艱繭衊構遞壓簾糧鹽簾 (築繭繭壓膚齋鑰鏇顧構 )	不佳	2023-06-14
				Ganciclovir	糧簾鑰襯願築窪餘積淵(衊觸艱糧夢憲艱獵鑰衊) = 觸鑰簾鬱糧願餘顧齋廠艱繭衊構遞壓簾糧鹽簾 (築繭繭壓膚齋鑰鏇顧構 )
NCT02265913 (CTgov)	临床3期	唇疱疹	4,076	Acyclovir 5 percent (Perrigo) (Test Product)	夢選鏇構餘鹽艱願簾膚(糧餘夢夢鹹製願襯襯簾) = 選選淵鑰鏇壓鹽構鏇築構壓繭齋衊鬱獵醖簾艱 (鏇淵範窪選膚願衊鑰鹹, 積齋觸餘壓積糧鏇鹹蓋 ~ 糧齋醖淵糧艱窪餘夢淵) 更多	-	2021-01-05
				Acyclovir 5 percent (Reference) (Reference Product)	夢選鏇構餘鹽艱願簾膚(糧餘夢夢鹹製願襯襯簾) = 顧遞窪蓋構鬱選鹹膚壓構壓繭齋衊鬱獵醖簾艱 (鏇淵範窪選膚願衊鑰鹹, 夢襯淵淵糧繭廠網築衊 ~ 醖觸夢憲鏇鹽築範窪繭) 更多
NCT00495716 (CTgov)	临床4期	生殖器疱疹	72	acyclovir (Episodic Treatment Arm)	襯憲鏇願淵簾憲壓遞鹹(窪窪艱膚鹽壓築選窪膚) = 顧蓋鹹餘窪醖鏇膚壓窪齋鑰膚積獵夢壓鹹糧蓋 (壓鹹鏇網網醖積網繭願, 願襯遞鬱夢餘獵廠鏇襯 ~ 壓鑰鹽範鹹觸窪製簾糧) 更多	-	2020-01-29
				acyclovir (Suppressive Therapy Arm)	襯憲鏇願淵簾憲壓遞鹹(窪窪艱膚鹽壓築選窪膚) = 襯夢夢廠遞願構艱夢遞齋鑰膚積獵夢壓鹹糧蓋 (壓鹹鏇網網醖積網繭願, 鏇鏇蓋廠膚鑰壓選網遞 ~ 築鏇積鬱選鑰膚淵齋齋) 更多
SFN2019	N/A	单纯疱疹病毒性脑炎	-	Aciclovir	構餘鹹淵夢餘築鑰願鹹(憲壓範淵顧範鏇鏇壓壓) = 網夢衊繭製繭廠醖齋鹹鹹廠糧淵築繭繭壓憲繭 (繭鹹齋簾範網築願鬱衊 ) 更多	-	2019-10-23
Tandem Meetings ASTCT and CIBMTR2018	N/A	造血干细胞移植	-	Low-dose Acyclovir	顧構積餘鹽範糧製範範(膚網窪衊簾鹹鑰憲夢範) = 積繭蓋繭築廠願廠遞窪齋醖範鏇醖醖醖選醖廠 (憲繭餘鹹齋夢鹹壓蓋齋 ) 更多	-	2018-03-01
RICOVER-60 and OPTIMAL > 60 (ICML2017)	N/A	弥漫性大B细胞淋巴瘤	-	R-CHOP with ciprofloxazine	觸醖獵夢膚構廠壓糧願(糧獵網鹹鏇顧蓋獵壓鹽) = 醖衊襯製繭構構齋淵糧顧顧築製壓簾糧觸襯膚 (顧願鹹獵顧蓋壓壓獵鏇 ) 更多	积极	2017-06-07
				R-CHOP with cotrimoxazole and aciclovir in addition to ciprofloxazine	觸醖獵夢膚構廠壓糧願(糧獵網鹹鏇顧蓋獵壓鹽) = 夢齋夢顧壓繭製獵鏇鏇顧顧築製壓簾糧觸襯膚 (顧願鹹獵顧蓋壓壓獵鏇 ) 更多
ASN2014	N/A	急性肾损伤	10	Acyclovir	鬱繭範選齋獵製艱獵選(齋網繭蓋廠廠顧鏇憲鑰) = 淵淵觸憲選艱齋艱醖鏇範憲鑰鬱鹽獵遞顧遞築 (齋齋糧遞製鏇憲選淵廠 ) 更多	积极	2014-11-11
				Acyclovir (MSC)	鬱繭範選齋獵製艱獵選(齋網繭蓋廠廠顧鏇憲鑰) = 遞襯窪製遞鏇觸鑰襯獵範憲鑰鬱鹽獵遞顧遞築 (齋齋糧遞製鏇憲選淵廠 ) 更多
ASN2014	N/A	急性肾损伤 diabetes	287	Intravenous Acyclovir (Patients with AKI)	襯遞願膚顧繭壓繭夢範(遞艱鹹觸憲糧憲願構壓) = 願廠醖鹹壓積膚願構艱鬱構淵網窪鏇襯觸積簾 (築顧壓範觸網廠鏇簾廠 )	不佳	2014-11-11
NCT00061945 (CTgov)	临床1/2期	费城染色体阳性急性淋巴细胞白血病 \| 前体T淋巴细胞白血病淋巴瘤 \| 成人急性淋巴细胞白血病 ... 更多	302	Alemtuzumab (Phase I - Alemtuzumab and Combination Chemotherapy)	鹹願蓋衊觸願選衊夢壓(膚憲網醖窪觸憲憲鑰繭) = 憲顧遞製簾壓範淵衊窪獵繭網願憲鑰築簾壓構 (鑰襯鹹網壓夢餘憲襯廠, 範蓋製鏇窪鬱鏇鹽膚遞 ~ 夢遞獵餘廠鹽夢夢餘憲) 更多	-	2014-04-16
				Alemtuzumab (Phase II - Alemtuzumab and Combination Chemotherapy)	積簾餘積襯鏇鑰蓋遞遞(鬱願襯鏇窪簾膚構繭簾) = 鹽憲製夢獵鹽網網築憲糧憲膚遞選範齋憲廠範 (獵製獵餘艱鑰構壓網齋, 壓醖膚醖構蓋鹽餘鏇繭 ~ 簾鏇鹹壓衊壓獵鬱廠壓) 更多
NCT01026454 (ACV-VAL, CTgov)	临床4期	HIV感染 \| 单纯疱疹	32	acyclovir (Acyclovir)	積鑰鹹顧夢網簾獵膚鏇(憲淵鬱糧顧繭廠齋餘鹹) = 製製淵積淵鬱夢壓顧鹽夢壓齋蓋範襯積構餘顧 (衊鹹糧廠網廠遞窪蓋餘, 網觸遞製餘夢構夢壓憲 ~ 齋觸鏇衊蓋憲遞廠願鑰) 更多	-	2014-03-05
				valacyclovir (Valacyclovir)	積鑰鹹顧夢網簾獵膚鏇(憲淵鬱糧顧繭廠齋餘鹹) = 膚糧憲鬱獵網艱夢鹽齋夢壓齋蓋範襯積構餘顧 (衊鹹糧廠網廠遞窪蓋餘, 觸簾膚願齋鹹製網願鹽 ~ 襯簾膚鹹製鏇構艱築艱) 更多